Adam J. Townsend - 15 Aug 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Commercial Officer
Signature
/s/ David Watson, attorney-in-fact for Adam Townsend
Issuer symbol
APLS
Transactions as of
15 Aug 2022
Net transactions value
-$673,875
Form type
4
Filing time
16 Aug 2022, 17:04:08 UTC
Previous filing
12 Aug 2022
Next filing
07 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $188,625 +12,500 +29% $15.09 55,407 15 Aug 2022 Direct F1
transaction APLS Common Stock Sale $862,500 -12,500 -23% $69.00 42,907 15 Aug 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -12,500 -3.7% $0.000000 327,500 15 Aug 2022 Common Stock 12,500 $15.09 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This is a scheduled exercise and sale form an established 10b5-1 plan.
F2 This represents a stock option granted 11/16/2018 that vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.